OUTLOOK Cost Of Revenue vs Current Deferred Revenue Analysis

OTLK Stock

USD 5.03 0.10 1.95%

OUTLOOK THERAPEUTICS financial indicator trend analysis is much more than just breaking down OUTLOOK THERAPEUTICS INC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OUTLOOK THERAPEUTICS INC is a good investment. Please check the relationship between OUTLOOK THERAPEUTICS Cost Of Revenue and its Current Deferred Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Cost Of Revenue vs Current Deferred Revenue

Cost Of Revenue vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OUTLOOK THERAPEUTICS INC Cost Of Revenue account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between OUTLOOK THERAPEUTICS's Cost Of Revenue and Current Deferred Revenue is -0.12. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of OUTLOOK THERAPEUTICS INC, assuming nothing else is changed. The correlation between historical values of OUTLOOK THERAPEUTICS's Cost Of Revenue and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of OUTLOOK THERAPEUTICS INC are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Cost Of Revenue i.e., OUTLOOK THERAPEUTICS's Cost Of Revenue and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.12

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on OUTLOOK THERAPEUTICS INC income statement and represents the costs associated with goods and services OUTLOOK THERAPEUTICS provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from OUTLOOK THERAPEUTICS's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OUTLOOK THERAPEUTICS INC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, OUTLOOK THERAPEUTICS's Tax Provision is quite stable compared to the past year. Issuance Of Capital Stock is expected to rise to about 47 M this year, although Enterprise Value Over EBITDA will most likely fall to (1.11).

	2021	2022	2023	2024 (projected)
Interest Expense	1.5M	1.6M	1.4M	1.9M
Depreciation And Amortization	204.7K	44.2K	39.8K	37.8K

Interest Expense Depreciation And Amortization

OUTLOOK THERAPEUTICS fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.47	-0.02	0.67	-0.3	-0.43	-0.02	0.21	0.17	0.19	-0.08	0.67	0.43	0.26	0.62	-0.32	0.19	0.43	0.59	0.68	0.23	0.27	-0.34	0.02	0.63	0.21
Short Long Term Debt Total	0.47		-0.46	0.85	-0.42	-0.2	0.19	-0.21	0.27	0.42	-0.39	0.2	0.69	-0.19	0.06	-0.1	0.5	0.69	-0.04	0.05	0.62	-0.19	-0.16	0.43	0.32	-0.23
Other Current Liab	-0.02	-0.46		-0.05	-0.51	0.33	-0.73	0.9	0.18	0.49	0.79	0.55	-0.85	0.89	0.58	0.14	-0.56	-0.85	0.55	0.45	-0.89	0.75	0.11	-0.03	0.54	0.9
Total Current Liabilities	0.67	0.85	-0.05		-0.65	-0.14	-0.11	0.2	0.29	0.61	-0.08	0.57	0.42	0.22	0.45	-0.08	0.23	0.42	0.33	0.4	0.28	0.13	-0.22	0.33	0.67	0.18
Total Stockholder Equity	-0.3	-0.42	-0.51	-0.65		-0.46	0.77	-0.68	-0.42	-0.89	-0.6	-0.77	0.28	-0.69	-0.69	-0.38	0.1	0.28	-0.58	-0.58	0.42	-0.72	0.11	-0.56	-0.89	-0.67
Other Liab	-0.43	-0.2	0.33	-0.14	-0.46		-0.73	0.4	-0.18	0.43	0.71	0.1	-0.61	0.38	0.17	0.94	-0.28	-0.61	0.09	0.09	-0.56	0.44	-0.07	0.14	0.23	0.4
Net Tangible Assets	-0.02	0.19	-0.73	-0.11	0.77	-0.73		-0.8	-0.12	-0.63	-0.93	-0.62	0.7	-0.8	-0.72	-0.66	0.46	0.7	-0.68	-0.65	0.82	-0.9	0.02	-0.33	-0.72	-0.79
Property Plant And Equipment Net	0.21	-0.21	0.9	0.2	-0.68	0.4	-0.8		0.09	0.67	0.84	0.7	-0.73	1.0	0.75	0.27	-0.48	-0.73	0.65	0.62	-0.8	0.84	-0.19	0.06	0.73	1.0
Current Deferred Revenue	0.17	0.27	0.18	0.29	-0.42	-0.18	-0.12	0.09		0.24	-0.07	0.48	0.11	0.09	0.12	-0.29	0.51	0.11	0.1	0.1	0.05	0.28	-0.06	0.38	0.34	0.09
Net Debt	0.19	0.42	0.49	0.61	-0.89	0.43	-0.63	0.67	0.24		0.48	0.55	-0.35	0.66	0.47	0.35	-0.18	-0.35	0.33	0.33	-0.39	0.53	-0.06	0.49	0.77	0.65
Retained Earnings	-0.08	-0.39	0.79	-0.08	-0.6	0.71	-0.93	0.84	-0.07	0.48		0.52	-0.81	0.83	0.69	0.6	-0.61	-0.81	0.64	0.59	-0.91	0.85	-0.03	0.15	0.56	0.83
Accounts Payable	0.67	0.2	0.55	0.57	-0.77	0.1	-0.62	0.7	0.48	0.55	0.52		-0.17	0.73	0.88	0.02	0.01	-0.17	0.8	0.82	-0.38	0.8	-0.29	0.23	0.93	0.69
Cash	0.43	0.69	-0.85	0.42	0.28	-0.61	0.7	-0.73	0.11	-0.35	-0.81	-0.17		-0.7	-0.27	-0.44	0.65	1.0	-0.25	-0.16	0.94	-0.6	-0.12	0.06	-0.22	-0.74
Non Current Assets Total	0.26	-0.19	0.89	0.22	-0.69	0.38	-0.8	1.0	0.09	0.66	0.83	0.73	-0.7		0.79	0.25	-0.48	-0.7	0.69	0.66	-0.79	0.85	-0.21	0.07	0.76	1.0
Non Currrent Assets Other	0.62	0.06	0.58	0.45	-0.69	0.17	-0.72	0.75	0.12	0.47	0.69	0.88	-0.27	0.79		0.15	-0.35	-0.27	0.97	0.97	-0.53	0.85	-0.16	0.23	0.87	0.74
Other Assets	-0.32	-0.1	0.14	-0.08	-0.38	0.94	-0.66	0.27	-0.29	0.35	0.6	0.02	-0.44	0.25	0.15		-0.27	-0.44	0.12	0.15	-0.4	0.35	-0.15	0.17	0.21	0.26
Long Term Debt	0.19	0.5	-0.56	0.23	0.1	-0.28	0.46	-0.48	0.51	-0.18	-0.61	0.01	0.65	-0.48	-0.35	-0.27		0.65	-0.43	-0.3	0.73	-0.32	-0.35	-0.05	-0.14	-0.48
Cash And Short Term Investments	0.43	0.69	-0.85	0.42	0.28	-0.61	0.7	-0.73	0.11	-0.35	-0.81	-0.17	1.0	-0.7	-0.27	-0.44	0.65		-0.25	-0.16	0.94	-0.6	-0.12	0.06	-0.22	-0.74
Net Receivables	0.59	-0.04	0.55	0.33	-0.58	0.09	-0.68	0.65	0.1	0.33	0.64	0.8	-0.25	0.69	0.97	0.12	-0.43	-0.25		0.98	-0.53	0.82	-0.03	0.25	0.79	0.65
Common Stock Total Equity	0.68	0.05	0.45	0.4	-0.58	0.09	-0.65	0.62	0.1	0.33	0.59	0.82	-0.16	0.66	0.97	0.15	-0.3	-0.16	0.98		-0.43	0.8	-0.18	0.23	0.81	0.62
Common Stock Shares Outstanding	0.23	0.62	-0.89	0.28	0.42	-0.56	0.82	-0.8	0.05	-0.39	-0.91	-0.38	0.94	-0.79	-0.53	-0.4	0.73	0.94	-0.53	-0.43		-0.76	-0.17	-0.1	-0.41	-0.8
Non Current Liabilities Total	0.27	-0.19	0.75	0.13	-0.72	0.44	-0.9	0.84	0.28	0.53	0.85	0.8	-0.6	0.85	0.85	0.35	-0.32	-0.6	0.82	0.8	-0.76		-0.12	0.31	0.79	0.84
Other Current Assets	-0.34	-0.16	0.11	-0.22	0.11	-0.07	0.02	-0.19	-0.06	-0.06	-0.03	-0.29	-0.12	-0.21	-0.16	-0.15	-0.35	-0.12	-0.03	-0.18	-0.17	-0.12		0.1	-0.21	-0.2
Other Stockholder Equity	0.02	0.43	-0.03	0.33	-0.56	0.14	-0.33	0.06	0.38	0.49	0.15	0.23	0.06	0.07	0.23	0.17	-0.05	0.06	0.25	0.23	-0.1	0.31	0.1		0.39	0.04
Total Liab	0.63	0.32	0.54	0.67	-0.89	0.23	-0.72	0.73	0.34	0.77	0.56	0.93	-0.22	0.76	0.87	0.21	-0.14	-0.22	0.79	0.81	-0.41	0.79	-0.21	0.39		0.72
Property Plant And Equipment Gross	0.21	-0.23	0.9	0.18	-0.67	0.4	-0.79	1.0	0.09	0.65	0.83	0.69	-0.74	1.0	0.74	0.26	-0.48	-0.74	0.65	0.62	-0.8	0.84	-0.2	0.04	0.72

Click cells to compare fundamentals

OUTLOOK THERAPEUTICS Account Relationship Matchups

OUTLOOK THERAPEUTICS fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.7M	22.8M	28.5M	32.3M	37.1M	25.7M
Short Long Term Debt Total	8.8M	11.9M	11.0M	35.6M	40.9M	42.9M
Other Current Liab	3.8M	1.7M	3.4M	920.0K	828.0K	786.6K
Total Current Liabilities	15.9M	6.8M	19.7M	46.7M	42.1M	44.2M
Total Stockholder Equity	2.8M	4.6M	8.7M	(14.4M)	(16.6M)	(17.4M)
Other Liab	4.2M	70.8K	522.9K	57.1K	51.4K	48.9K
Net Tangible Assets	(16.1M)	2.8M	4.6M	8.7M	10.0M	10.5M
Property Plant And Equipment Net	494.2K	275.1K	70.4K	26.2K	23.6K	22.4K
Net Debt	(3.7M)	(2.6M)	(6.4M)	12.2M	10.9M	5.9M
Retained Earnings	(289.7M)	(342.9M)	(408.9M)	(467.9M)	(421.1M)	(400.1M)
Accounts Payable	2.4M	2.2M	3.5M	6.6M	5.9M	4.1M
Cash	12.5M	14.5M	17.4M	23.4M	26.9M	28.2M
Non Current Assets Total	1.8M	1.3M	1.0M	1.3M	1.2M	1.1M
Non Currrent Assets Other	394.4K	174.6K	132.0K	501.3K	451.2K	502.1K
Other Assets	449.0	(451.0)	132.0K	399.0	359.1	341.15
Long Term Debt	98.5K	50.3K	904.2K	10.9M	12.5M	13.1M
Cash And Short Term Investments	12.5M	14.5M	17.4M	23.4M	26.9M	28.2M
Common Stock Total Equity	286.1K	1.3M	1.8M	2.3M	2.0M	1.9M
Common Stock Shares Outstanding	3.6M	7.6M	10.6M	12.5M	14.4M	15.1M
Liabilities And Stockholders Equity	19.7M	22.8M	28.5M	32.3M	37.1M	25.7M
Non Current Liabilities Total	1.0M	11.5M	61.4K	7K	6.3K	6.0K
Other Current Assets	4.6M	7.0M	10.1M	7.6M	8.7M	8.3M
Other Stockholder Equity	291.3M	345.7M	(28.5T)	450.9M	405.8M	426.1M
Total Liab	16.9M	18.2M	19.8M	46.7M	42.1M	28.2M
Property Plant And Equipment Gross	494.2K	1.2M	1.1M	26.2K	23.6K	22.4K
Short Long Term Debt	3.7M	904.2K	10.9M	35.6M	40.9M	42.9M
Total Current Assets	17.9M	21.5M	27.5M	31.0M	35.6M	37.4M
Accumulated Other Comprehensive Income	(19.7T)	(22.8T)	417.7M	(32.3T)	(29.1T)	(27.6T)
Short Term Debt	7.9M	973.5K	11.0M	35.6M	40.9M	42.9M
Common Stock	1.3M	1.8M	2.3M	2.6M	2.3M	3.9M
Property Plant Equipment	3.2M	327.2K	163.6K	70.4K	63.3K	60.2K
Long Term Debt Total	3.6M	3.4M	904.2K	10.9M	12.5M	6.4M
Retained Earnings Total Equity	(254.5M)	(289.7M)	(342.9M)	(408.9M)	(368.0M)	(386.4M)
Capital Surpluse	238.1M	291.3M	345.7M	415.4M	477.7M	278.9M
Capital Lease Obligations	4.2M	112.3K	43.0K	4.3K	3.8K	3.6K
Non Current Liabilities Other	3.9M	113.3K	565.9K	61.4K	55.3K	52.5K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether OUTLOOK THERAPEUTICS INC is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if OUTLOOK Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Outlook Therapeutics Inc Stock. Highlighted below are key reports to facilitate an investment decision about Outlook Therapeutics Inc Stock:

How To Invest In OUTLOOK

Details

Is OUTLOOK Stock a good investment?

Details

What is OUTLOOK THERAPEUTICS's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.89)

Revenue Per Share

0.119

Quarterly Revenue Growth

6.583

Return On Assets

(0.84)

Return On Equity

(0.04)

The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

OUTLOOK Cost Of Revenue vs Current Deferred Revenue Analysis

Cost Of Revenue vs Current Deferred Revenue

Cost Of Revenue vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Current Deferred Revenue

OUTLOOK THERAPEUTICS fundamental ratios Correlations

OUTLOOK THERAPEUTICS Account Relationship Matchups

High Positive Relationship

High Negative Relationship

OUTLOOK THERAPEUTICS fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Non Current Assets Total
Common Stock Total Equity	+ 0.98	Net Receivables
Net Receivables	+ 0.97	Non Currrent Assets Other

Retained Earnings	- 0.93	Net Tangible Assets
Common Stock Shares Outstanding	- 0.91	Retained Earnings
Non Current Liabilities Total	- 0.9	Net Tangible Assets
Total Liab	- 0.89	Total Stockholder Equity
Net Debt	- 0.89	Total Stockholder Equity
Common Stock Shares Outstanding	- 0.89	Other Current Liab